Where does Ancora Heart, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Ancora Heart, Inc. ranks #11,539 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Ancora Heart, Inc. hold?

Ancora Heart, Inc. holds 26 US utility patents granted between 2017 and 2025, spanning 5 technology areas.

What is Ancora Heart, Inc.'s Innovation Score?

Ancora Heart, Inc. has an Innovation Score of 33.0 out of 100 (43rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Ancora Heart, Inc. focus on?

Ancora Heart, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 25 patents, ranking #733 of 7,127 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Ancora Heart, Inc.'s patent grant rate increasing or decreasing?

Ancora Heart, Inc.'s recent grant velocity is +50% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Ancora Heart, Inc.'s patents?

Ancora Heart, Inc.'s patents average 17.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Ancora Heart, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Ancora Heart, Inc.

USPTO PatentsView assignee record - 26 granted patents across 5 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Ancora ranks #11,539 of 49,997 tracked US assignees by granted-patent volume, with 26 patents across 5 technology areas.

#11,539
of 49,997 US assignees by volume: 43rd percentile
by Innovation Score (33.0/100): 17.8
avg claims per patent: +50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11539 · US Corporation #11,539 · 26 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 26 grants
UPPER-Q #11,539/49,997
PHOTO-FINISH Aker Subsea AS
CPC-NARROW A61B · 5 areas
INNOV-THIN 33.0/100
CLAIMS-RICH 17.8 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Aker Subsea AS (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Ancora’s 33.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.4 pts (35%) Velocity 3.0 pts (9%) Breadth 7.9 pts (24%) Claim depth 10.7 pts (32%)

Qualcomm Incorporated · highest

85
Ancora Heart · this assignee

33
Crimson Consulting · near

33
Guangdong Gopod… · near

33
Hydrojug · near

33
Jenoptik Robot · near

33
3D Lighting… · lowest

7

What this shows Ancora's Innovation Score is 33.0/100 (43rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Ancora?

Each dot is one of Ancora’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ancora’s own 17.8 claims/patent is ABOVE the 14.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Ancora vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Ancora's grants concentrate

Ancora Heart, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 96.2% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2020 (6 grants) versus a trough of 1 in 2019. By volume, Ancora sits between Aker Subsea AS and Ariat International, Inc..

Ancora's three-year grant acceleration

Ancora Heart, Inc. shows 5 grants in 2022–2024 against only 11 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Aker Subsea AS

26
Alfred Kaercher S…

26
Allied Bioscience

26
American Piledriv…

26
Apex Tactical Spe…

26
Ares

26
Areva NC

26
Ariat Internation…

26
Ancora Heart ◀

26

What this shows Ancora holds 26 patents at rank #11,552, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Ancora

By rank, the assignees closest to #11,552 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Ancora's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Ancora, neither rank-band nor same-CPC leaders (those blocks stay above). In A61B (Diagnosis), Ancora ranks #733 of 7,127 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (33 here).

Crimson Consulting Limited 33 Hydrojug, Inc. 33 Guangdong Gopod Group Holding Co., Ltd. 33 Jenoptik Robot GmbH 33

Ancora's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 43rd percentile higher than 43% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Ancora Heart, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	4	15.4%
2018	5	19.2%
2019	1	3.8%
2020	6	23.1%
2021	4	15.4%
2023	1	3.8%
2024	4	15.4%
2025partial year	1	3.8%

Which technologies does Ancora Heart, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 25

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 14

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 10

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 1

D07B - Ropes OR Cables IN General 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Ancora Heart, Inc.'s patent record in context - here's where to go next.

Ancora Heart, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 96.2% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #11,539 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Ancora Heart, Inc. against Aker Subsea AS, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 33.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.